Loading organizations...
BIOND Solutions is a biotechnology hardware company based in Delft, Netherlands, that develops organ-on-chip technologies and 3D microfluidic cell cultures for in vitro drug testing and personalized medicine research. The company manufactures customizable semiconductor microchips that allow pharmaceutical companies, hospitals, and contract research organizations to culture human cells in dynamic environments mimicking human physiology prior to clinical trials. To support its manufacturing and operational scaling, the enterprise has raised over €4 million in total funding across multiple rounds and maintains an estimated workforce of fifteen to fifty employees. The firm operates as an academic spin-off from Delft University of Technology and has secured financial backing from notable institutional investors, including FORWARD.one and the European Innovation Council Fund. BIOND Solutions was officially founded in 2017 by its co-founders Cinzia Silvestri, Nikolas Gaio, and William F. Quiros Solano.
BIOND Solutions has raised $4.0M across 1 funding round.
BIOND Solutions has raised $4.0M in total across 1 funding round.
BIOND Solutions has raised $4.0M in total across 1 funding round.
BIOND Solutions's investors include FORWARD.one.
BIOND Solutions has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $4M Seed | — | FORWARD.one | Announced |
BIOND Solutions (Bi/ond) is a biotechnology startup founded in 2017 as a spin-off from Delft University of Technology in the Netherlands, specializing in organ-on-chip technology.[1][2][3][4] The company develops semiconductor microchips that nourish, stimulate, and monitor human cells and 3D tissues in vitro, enabling more accurate drug testing and personalized medicine for research institutes, pharmaceutical companies, and biotech firms.[1][2][3] Products like inCHIPit™ (versatile organ-on-chip for complex 3D tissues) and MUSbit™ (for contractile muscle tissue with microfluidic channels) recreate organ functions such as heart beating and blood circulation, serving biologists, hospitals, and CROs while adhering to 3Rs principles (replace, reduce, refine animal testing).[2][7] With a team blending engineers and biologists, Bi/ond addresses genetic diversity in treatments, providing human-like data to reduce clinical trial failures.[1][2]
Bi/ond emerged in 2017 from Delft University of Technology, driven by co-founders Dr. Cinzia Silvestri (CEO, expertise in microelectronics and 3D tissue biology), Dr. Nikolas Gaio (CTO, microelectronics and biological solutions), and Dr. William Fausto Quiros Solano (CSO).[1][3][4] Their combined 15-20+ years of experience bridged engineering and biology to create chips mimicking human tissues, inspired by the need for personalized medicine amid genetic variations ignored by traditional drugs.[1][2][3] Early traction included collaborations with European hospitals and research centers, a €250,000 investment from UNIIQ in 2020 for team expansion (to 11 members, 50% engineers/50% biologists), R&D, and IP protection, plus participation in the MAGIC project for genetic therapies in muscular dystrophies using iPSCs.[1][3] Pivotal moments involved scaling patented technology for heart, lung, brain, and cancer models.[3][4]
Bi/ond rides the organ-on-chip and microphysiological systems trend, accelerating personalized medicine and reducing 90%+ drug failure rates in trials by providing human-relevant data pre-clinically.[1][2][3] Timing aligns with rising iPSC use, AI-driven biology, and EU pushes for 3Rs (e.g., animal testing bans by 2025 in cosmetics), favoring hardware enabling diverse tissue models for diseases like muscular dystrophy, cancer, and neurodegeneration.[1][2][7] Market forces include €multi-billion organ-on-chip growth (CAGR 30%+), pharma demand for efficient R&D amid rising costs, and spin-off momentum from TU Delft's ecosystem.[3][4] Bi/ond influences by bridging engineering-biology gaps, empowering CROs/pharma with scalable tools, and advancing genetic therapies via projects like MAGIC, contributing to a shift toward animal-free, patient-specific biotech.[1][7]
Bi/ond is poised for expansion through commercialization of inCHIPit™ and MUSbit™, leveraging UNIIQ funding, IP, and partnerships to target pharma pipelines and personalized treatments.[3][4] Upcoming trends like AI-integrated organ-chips, broader iPSC adoption, and regulatory incentives for 3Rs will amplify growth, potentially scaling to new tissues (brain, lung) and global markets.[1][2] Influence may evolve via acquisitions by big pharma or further spin-offs, solidifying its role in inclusive drug development—echoing its founding mission to engineer microchips that finally make medicines as unique as we are.[1][2]
